MedTrace Logo

Investigation of the Safety and Efficacy of Renzapride in Constipation Predominant Irritable Bowel Syndrome (IBS)

NCT00268879 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 1821

Last updated 2008-02-15

No results posted yet for this study

Summary

The purpose of the study is to investigate whether renzapride will help alleviate the symptoms associated with constipation predominant irritable bowel syndrome in female patients.

Conditions

  • Irritable Bowel Syndrome

Interventions

DRUG

Renzapride

Placebo Renzapride 4 mg QD Renzapride 2 mg BID

Sponsors & Collaborators

  • Alizyme

    lead INDUSTRY

Principal Investigators

  • Anthony Lembo · Beth Israel Deaconess Medical Centre, Boston

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-12-31
Primary Completion
2008-01-31
Completion
2008-01-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00268879 on ClinicalTrials.gov